

Angela J Okragly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2893910/publications.pdf>

Version: 2024-02-01

13
papers

564
citations

932766

10
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

678
citing authors

#	ARTICLE	IF	CITATIONS
1	ELEVATED TRYPTASE, NERVE GROWTH FACTOR, NEUROTROPHIN-3 AND GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR LEVELS IN THE URINE OF INTERSTITIAL CYSTITIS AND BLADDER CANCER PATIENTS. <i>Journal of Urology</i> , 1999, 161, 438-442.	0.2	217
2	An Acid-Treatment Method for the Enhanced Detection of GDNF in Biological Samples. <i>Experimental Neurology</i> , 1997, 145, 592-596.	2.0	106
3	Cervical Dorsal Rhizotomy Increases Brain-Derived Neurotrophic Factor and Neurotrophin-3 Expression in the Ventral Spinal Cord. <i>Journal of Neuroscience</i> , 2000, 20, RC77-RC77.	1.7	49
4	LIGHTÆ deficiency impairs CD8+ T cell expansion, but not effector function. <i>International Immunology</i> , 2003, 15, 861-870.	1.8	40
5	IL-33 released by alum is responsible for early cytokine production and has adjuvant properties. <i>Scientific Reports</i> , 2015, 5, 13146.	1.6	37
6	GDNF is abundant in the adult rat gut. <i>Journal of the Autonomic Nervous System</i> , 1998, 70, 115-122.	1.9	35
7	Tumor-derived death receptor 6 modulates dendritic cell development. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 777-787.	2.0	21
8	Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP). <i>Cephalalgia</i> , 2018, 38, 1564-1574.	1.8	17
9	Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production. <i>Frontiers in Immunology</i> , 2018, 9, 2871.	2.2	15
10	Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis. <i>Cytokine</i> , 2016, 79, 66-73.	1.4	10
11	Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3823-3835.	1.6	6
12	Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2022, 187, 599-602.	1.4	6
13	Facile generation and use of immunogenic polypeptide fusions to a sparingly soluble non-antigenic protein carrier. <i>Journal of Immunological Methods</i> , 2000, 236, 53-69.	0.6	5